BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Groneberg DA, Paul H, Welte T. Novel strategies of aerosolic pharmacotherapy. Exp Toxicol Pathol 2006;57 Suppl 2:49-53. [PMID: 16580826 DOI: 10.1016/j.etp.2006.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee HJ, Kwon YB, Kang JH, Oh DW, Park ES, Rhee YS, Kim JY, Shin DH, Kim DW, Park CW. Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. J Control Release 2021;329:468-81. [PMID: 32871206 DOI: 10.1016/j.jconrel.2020.08.050] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Park C, Li X, Vogt FG, Hayes D, Zwischenberger JB, Park E, Mansour HM. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. International Journal of Pharmaceutics 2013;455:374-92. [DOI: 10.1016/j.ijpharm.2013.06.047] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
3 Brandsch M, Knütter I, Bosse-doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. Journal of Pharmacy and Pharmacology 2008;60:543-85. [DOI: 10.1211/jpp.60.5.0002] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 13.4] [Reference Citation Analysis]
4 Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010;10:699-711. [PMID: 20883966 DOI: 10.1016/S1473-3099(10)70157-2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 32] [Article Influence: 7.1] [Reference Citation Analysis]
5 Buckley ST, Kim K, Ehrhardt C. In Vitro Cell Culture Models for Evaluating Controlled Release Pulmonary Drug Delivery. In: Smyth HD, Hickey AJ, editors. Controlled Pulmonary Drug Delivery. New York: Springer; 2011. pp. 417-42. [DOI: 10.1007/978-1-4419-9745-6_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhou Y, Sun J, Cheng YS. Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles. J Aerosol Med Pulm Drug Deliv 2011;24:277-84. [PMID: 21732711 DOI: 10.1089/jamp.2011.0882] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
7 Wagner U, Staats P, Fehmann HC, Fischer A, Welte T, Groneberg DA. Analysis of airway secretions in a model of sulfur dioxide induced chronic obstructive pulmonary disease (COPD). J Occup Med Toxicol 2006;1:12. [PMID: 16759388 DOI: 10.1186/1745-6673-1-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
8 Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv 2009;6:941-59. [PMID: 19637979 DOI: 10.1517/17425240903117244] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]